ArticleBiomarkers in neuropsychiatry2021
BIOMARKERS AND NEUROBEHAVIORAL DIAGNOSIS.
Article in Biomarkers in neuropsychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Using physiological biomarkers in forensic psychiatry: a scoping review.Frontiers in psychiatry · 2025Pooled it
- Biomarkers for mood disorders: A scoping review of research from India.Indian journal of psychiatry · 2026Review
- Autism Symptom Presentation and Hierarchical Models of Intelligence.Journal of autism and developmental disorders · 2026Article
- Just Semantics? How Diagnostic Criteria Influence Physician-Patient Narratives in Alzheimer's Disease.Neuro-degenerative diseases · 2026Article
- Exosomes as Emerging Therapeutic Platforms in Neurological and Psychiatric Disorders.Pharmaceutical medicine · 2025Review
- Face perception, attention, and memory as predictors of social change in autistic children.Journal of neurodevelopmental disorders · 2025Observational
- The GREENBEAN checklist for reporting studies evaluating the effectiveness of EEG-based biomarkers.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2025Review
- Leveraging AI-Driven Neuroimaging Biomarkers for Early Detection and Social Function Prediction in Autism Spectrum Disorders: A Systematic Review.Healthcare (Basel, Switzerland) · 2025Review
- Editorial: Neuroimaging in psychiatry 2023: mood disorders.Frontiers in psychiatry · 2025Article
- REVEALS: an open-source multi-camera GUI for rodent behavior acquisition.Cerebral cortex (New York, N.Y. : 1991) · 2024Article
- Evaluating causal psychological models: A study of language theories of autism using a large sample.Frontiers in psychology · 2023Article
- Independent evaluation of the harvard automated processing pipeline for Electroencephalography 1.0 using multi-site EEG data from children with Fragile X Syndrome.Journal of neuroscience methods · 2022Article
- Dissociation in Neural Correlates of Hyperactive/Impulsive vs. Inattentive Symptoms in Attention-Deficit/Hyperactivity Disorder.Frontiers in neuroscience · 2022Article
- RNA biomarkers for alcohol use disorder.Frontiers in molecular neuroscience · 2022Review
- Associations between Task-Related Modulation of Motor-Evoked Potentials and EEG Event-Related Desynchronization in Children with ADHD.Cerebral cortex (New York, N.Y. : 1991) · 2021Article
- Invasive Electrophysiology for Circuit Discovery and Study of Comorbid Psychiatric Disorders in Patients With Epilepsy: Challenges, Opportunities, and Novel Technologies.Frontiers in human neuroscience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Our current diagnostic methods for treatment planning in Psychiatry and Neurodevelopmental Disabilities leave room for improvement, and null results in clinical trials in these fields may be a result of insufficient tools for patient stratification. Great hope has been placed in novel technologies to improve clinical and trial outcomes, but we have yet to see a substantial change in clinical practice. As we examine attempts at biomarker validation within these fields, we find that it may be the diagnoses themselves that fall short. We now need to improve neuropsychiatric nosologies with a focus on validity based not solely on behavioral features, but on a synthesis that includes genetic and biological data as well. The eventual goal is diagnostic biomarkers and diagnoses themselves based on distinct mechanisms, but such an understanding of the causal relationship across levels of analysis is likely to be elusive for some time. Rather, we propose an approach in the near-term that deconstructs diagnosis into a series of independent, empiric and clinically relevant associations among a single, defined patient group, a single biomarker, a single intervention and a single clinical outcome. Incremental study across patient groups, interventions, outcomes and modalities will lead to a more interdigitated network of knowledge, and correlations in metrics across levels of analysis will eventually give way to the causal understanding that will allow for mechanistically based diagnoses.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.